Piper Sandler initiated coverage of UroGen Pharma (URGN) with an Overweight rating and $36 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- UroGen Pharma’s Earnings Call: Achievements and Challenges
- UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
- UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
- Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
- UroGen Pharma reports Q2 EPS ($1.05), consensus (83c)